NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer.
NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer.
复制标题
NIH 共识会议。
DOI：
--
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
J. Gioanni
中科院分区：
文献类型：
--
作者：
N. Cattan;N. Rochet;C. Mazeau;E. Zanghellini;B. Mari;C. Chauzy;H. D. Novion;J. Amiel;J. Lagrange;B. Rossi;J. Gioanni
目的
为医生提供关于卵巢癌筛查、预防、诊断和治疗的最新共识。
参与者
一个非联邦、非倡导者、14名成员的共识小组，代表妇科、医学和放射肿瘤学、产科/妇科和生物统计学领域; 25名产科/妇科和妇科、医学和放射肿瘤学专家向共识小组提交数据;会议观众约500人。
证据
通过MEDLINE检索文献，并为专家组和会议观众制作了广泛的参考书目。专家们编写了摘要，并引用了相关文献。科学证据优先于临床经验。
共识
该小组回答了预先确定的共识问题，并根据公开论坛和科学文献中提出的科学证据得出了结论。
共识声明
小组编写了一份声明草稿，全文宣读并分发给专家和听众征求意见。该小组解决了相互矛盾的建议，并在会议结束时发布了一份修订后的声明。专家组在会议结束后几周内完成了修订。
结论
目前还没有证据表明CA-125和经阴道超声检查的筛查方式可以有效地用于广泛的筛查，以降低卵巢癌的死亡率，也没有证据表明它们的使用会导致发病率和死亡率的降低而不是增加。患有IA 1级和IB 1级卵巢癌的女性不需要术后辅助治疗。许多剩余的I期患者确实需要化疗。I期的亚组必须完全定义，并确定理想的治疗。II、III、IV期卵巢上皮癌（低恶性潜能肿瘤除外）患者应接受术后化疗。
OBJECTIVE
To provide physicians with a current consensus on screening, prevention, diagnosis, and treatment of ovarian cancer.
PARTICIPANTS
A nonfederal, nonadvocate, 14-member consensus panel representing the fields of gynecologic, medical, and radiation oncology, obstetrics/gynecology, and biostatistics; 25 experts in obstetrics/gynecology and gynecologic, medical, and radiation oncology who presented data to the consensus panel; and a conference audience of approximately 500.
EVIDENCE
The literature was searched through MEDLINE, and an extensive bibliography of references was produced for the panel and the conference audience. Experts prepared abstracts with relevant citations from the literature. Scientific evidence was given priority over clinical anecdotal experience.
CONSENSUS
The panel, answering predefined consensus questions, developed their conclusions based on the scientific evidence presented in open forum and the scientific literature.
CONSENSUS STATEMENT
The panel composed a draft statement that was read in its entirety and circulated to the experts and the audience for comment. The panel resolved conflicting recommendations and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference.
CONCLUSIONS
There is no evidence available yet that the current screening modalities of CA-125 and transvaginal ultrasonography can be effectively used for widespread screening to reduce mortality from ovarian cancer nor that their use will result in decreased rather than increased morbidity and mortality. Women with stage IA grade 1 and stage IB grade 1 ovarian cancer do not require postoperative adjuvant therapy. Many remaining stage I patients do require chemotherapy. Subsets of stage I must be fully defined and ideal treatment determined. Women with stages II, III, and IV epithelial ovarian cancer (other than low malignant potential tumors) should receive postoperative chemotherapy.